Piotr Stola, MD
Pulmonary Disease · Mesa, AZNPI 1942248604
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,130 of the $9,197 with a category attached, or 88.4%. It is spread thinly across 45 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,333, 2.8 times the $832 reported in 2019.
Across 362 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$1K
- GSK$783
- AstraZeneca$777
- Jazz Pharmaceuticals Inc.$688
- Grifols USA, LLC$542
- Cook Incorporated$490
- plus $5K from 39 others
What the payments were for
- Travel & lodging$8289%
- Food & beverage$8,13088%
- Education$2383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$917
- Melker$490
- FASENRA$255
- FLOWTRIEVER CATHETER, S$143
- CT THROMBECTOMY SYSTEM KIT$143
- BREZTRI$132
- FARXIGA$132
- TEZSPIRE$132
- XYWAV$122
- Monarch Platform$119
- XT CDX$115
How this compares
$9,197 in reported general payments places this provider in the 70th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 218 | $165,233 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 113 | $70,859 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 75 | $60,008 |
| Dupixent PenDupilumab | 13 | $57,382 |
| Dupixent SyringeDupilumab | 12 | $43,493 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $40,771 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $27,699 |
| Spiriva RespimatTiotropium Bromide | 19 | $15,958 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $8,829 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $7,996 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 213 | $5,317 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $4,589 |
| Roflumilast | 29 | $2,382 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,251 |
| Azelastine Hcl | 28 | $825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $783 | $272,620403 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $451 | $75,96694 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $777 | $48,76785 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Mesa
- George ParidesMesa$913K
- Mukesh AhluwaliaMesa$25K
- Steven FarberMesa$22K
- Rajat WaliaPhoenix$748K
- Abhinav MittalTucson$570K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Richard SueGilbert$224K
- Mark GotfriedPhoenix$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.